계명대학교 의학도서관 Repository

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Metadata Downloads
Author(s)
Sung-Eun LeeSoo Young ChoiHye-Young SongSoo-Hyun KimMi-Yeon ChoiJoon Seong ParkHyeoung-Joon KimSung-Hyun KimDae Young ZangSukjoong OhHawk KimYoung Rok DoJae-Yong KwakJeong-A KimDae-Young KimYeung-Chul MunWon Sik LeeMyung Hee ChangJinny ParkJi Hyun KwonDong-Wook Kim
Keimyung Author(s)
Do, Young Rok
Department
Dept. of Internal Medicine (내과학)
Journal Title
Haematologica.
Issued Date
2016
Volume
101
Issue
6
Abstract
The aim of the Korean Imatinib Discontinuation Study was to
identify predictors for safe and successful imatinib discontinuation.
A total of 90 patients with a follow-up of ≥12 months were
analyzed. After a median follow-up of 26.6 months after imatinib discontinuation,
37 patients lost the major molecular response. The probability
of sustained major molecular response at 12 months and 24
months was 62.2% and 58.5%, respectively. All 37 patients who lost
major molecular response were retreated with imatinib therapy for a
median of 16.9 months, and all achieved major molecular response
again at a median of 3.9 months after resuming imatinib therapy. We
observed newly developed or worsened musculoskeletal pain and pruritus
in 27 (30%) patients after imatinib discontinuation. Imatinib withdrawal
syndrome was associated with a higher probability of sustained
major molecular response (P=0.003) and showed a trend for a longer
time to major molecular response loss (P=0.098). Positivity (defined as ≥
17 positive chambers) of digital polymerase chain reaction at screening
and longer imatinib duration before imatinib discontinuation were associated
with a higher probability of sustained major molecular response.
Our data demonstrated that the occurrence of imatinib withdrawal syndrome
after imatinib discontinuation and longer duration of imatinib
were associated with a lower rate of molecular relapse. In addition, minimal
residual leukemia measured by digital polymerase chain reaction
had a trend for a higher molecular relapse.
Keimyung Author(s)(Kor)
도영록
Publisher
School of Medicine
Citation
Sung-Eun Lee et al. (2016). Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica., 101(6), 717–723. doi: 10.3324/haematol.2015.139899
Type
Article
ISSN
0390-6078
DOI
10.3324/haematol.2015.139899
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/33216
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.